Comparative Pharmacology
Head-to-head clinical analysis: PANTOPRAZOLE SODIUM versus PROTONIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANTOPRAZOLE SODIUM versus PROTONIX.
PANTOPRAZOLE SODIUM vs PROTONIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor. Suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
Proton pump inhibitor that inhibits the H+/K+-ATPase enzyme system at the secretory surface of gastric parietal cells, blocking the final step of gastric acid secretion.
40 mg orally once daily for 8 weeks for erosive esophagitis; 40 mg intravenously once daily for 7-10 days for GERD with esophagitis.
40 mg orally once daily; alternatively, 40 mg IV once daily for 7-10 days.
None Documented
None Documented
Terminal elimination half-life: ~1 hour (range 0.5–2 h); clinically, acid suppression lasts longer due to covalent binding to proton pumps
Terminal elimination half-life is about 1–2 hours in healthy individuals; in CYP2C19 poor metabolizers or hepatic impairment, half-life may increase up to 3–6 hours, but clinical impact is minimal due to irreversible binding to H+/K+-ATPase.
Renal: ~71% as metabolites; fecal: ~18% via bile; unchanged renal excretion: <1%
Approximately 80% of a dose is excreted as metabolites in urine, with the remainder (≈20%) in feces via biliary elimination.
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor